{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?questionFirstAnswered.=2019-02-12T15%3A49%3A07.43Z&max-date=2019-07-18", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?questionFirstAnswered.=2019-02-12T15%3A49%3A07.43Z&max-date=2019-07-18", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?questionFirstAnswered.=2019-02-12T15%3A49%3A07.43Z&max-date=2019-07-18&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&questionFirstAnswered.=2019-02-12T15%3A49%3A07.43Z&max-date=2019-07-18", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?questionFirstAnswered.=2019-02-12T15%3A49%3A07.43Z&max-date=2019-07-18", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?questionFirstAnswered.=2019-02-12T15%3A49%3A07.43Z&max-date=2019-07-18", "items" : [{"_about" : "http://data.parliament.uk/resources/1054660", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1054660/answer", "answerText" : {"_value" : "
The Department has no plans currently. The National Institute for Health and Care Excellence is currently developing guidance on Brineura (Cerliponase alfa) for treating neuronal ceroid lipofuscinosis type 2 under the highly specialised technology programme. Further information can be found at the following link:<\/p>
<\/p>